IP Library Granted Patent US 8,221,979
Granted Patent B2
US 8,221,979 · App. 12/443,752 · Granted Jul 17, 2012

Compositions and methods for detecting Noonan syndrome

Assignees: Mount Sinai School of Medicine; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,979
App. No.
12/443,752
Granted
Jul 17, 2012
Kind
B2
Abstract

Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.

Claims (30)

1. A method for diagnosing Noonan syndrome in a human subject, comprising amplifying all or part of a RAS-specific guanine nucleotide exchange factor (SOS1) nucleic acid molecule from a biological sample of the subject, and detecting a mutation in the SOS1 nucleic acid molecule, wherein the mutation results in an SOS1 polypeptide comprising an amino acid substitution at a position selected from the group consisting of:

(a) a W to R substitution at position 432 of SEQ ID NO:4;

(b) an E to K substitution at position 433 of SEQ ID NO:4; and

(c) a C to Y substitution at position 441 of SEQ ID NO:4,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

2. The method of claim 1 , wherein the mutation in the SOS1 nucleic acid molecule is selected from the group consisting of:

(a) a T to C substitution at position 1294 of SEQ ID NO:3;

(b) a G to A substitution at position 1297 of SEQ ID NO:3; and

(c) a G to A substitution at position 1322 of SEQ ID NO:3,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

3. A method for diagnosing Noonan syndrome in a human subject, comprising obtaining a biological sample from the subject, and detecting a mutation in a RAS-specific guanine nucleotide exchange factor (SOS1) nucleic acid molecule from the sample, wherein the mutation results in an SOS1 polypeptide comprising an amino acid substitution at a position selected from the group consisting of:

(a) a W to R substitution at position 432 of SEQ ID NO:4;

(b) an E to K substitution at position 433 of SEQ ID NO:4; and

(c) a C to Y substitution at position 441 of SEQ ID NO:4,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

4. The method of claim 3 , wherein the mutation in the SOS1 nucleic acid molecule is selected from the group consisting of:

(a) a T to C substitution at position 1294 of SEQ ID NO:3;

(b) a G to A substitution at position 1297 of SEQ ID NO:3; and

(c) a G to A substitution at position 1322 of SEQ ID NO:3,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

5. A method for diagnosing Noonan syndrome in a human subject, comprising sequencing all or part of a RAS-specific guanine nucleotide exchange factor (SOS1) nucleic acid molecule from the subject, and detecting a mutation in the SOS1 nucleic acid molecule, wherein the mutation results in an SOS1 polypeptide comprising an amino acid substitution at a position selected from the group consisting of:

(a) a W to R substitution at position 432 of SEQ ID NO:4;

(b) an E to K substitution at position 433 of SEQ ID NO:4; and

(c) a C to Y substitution at position 441 of SEQ ID NO:4,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

6. The method of claim 5 , wherein the mutation in the SOS1 nucleic acid molecule is selected from the group consisting of:

(a) a T to C substitution at position 1294 of SEQ ID NO:3;

(b) a G to A substitution at position 1297 of SEQ ID NO:3; and

(c) a G to A substitution at position 1322 of SEQ ID NO:3,

and wherein the presence of said mutation in said SOS1 nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 11, 2009
From: MOUNT SINAI SCHOOL OF MEDICINE OF NYU
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023638/0817 →
CONFIRMATORY LICENSE Recorded Jul 8, 2009
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 022933/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2009
From: GELB, BRUCE D.; TARTAGLIA, MARCO
To: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
Reel/Frame 022860/0669 →
Continuity (2)
Provisional Application 60866204 · Nov 16, 2006
Related Publication 20100009361A1 · Jan 14, 2010